Business Description
ContraFect Corp
NAICS : 325412
SIC : 2834
ISIN : US2123261024
Description
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History |
|---|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ContraFect Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -18.14 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -34.93 | ||
| 3-Year Sortino Ratio | -3.45 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 4.984 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 4.984 - 4.984 | ||
| Shares Outstanding (Mil) | 10.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ContraFect Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ContraFect Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-02 | In 116 days | ||
| Second quarter earnings results for 2026 | 2026-08-17 | In 39 days | ||
| First quarter earnings results for 2026 | 2026-07-14 | In 5 days | ||
| 0.0125:1 Stock Split | 2023-02-15 | 4.98 (+0.00%) | ||
| 0.1:1 Stock Split | 2020-02-04 | -- |
Show
Entries
ContraFect Corp Frequently Asked Questions
What is ContraFect Corp(STU:22R)'s stock price today?
The current price of STU:22R is €4.98. The 52 week high of STU:22R is €4.98 and 52 week low is €4.98.
When is next earnings date of ContraFect Corp(STU:22R)?
The next earnings date of ContraFect Corp(STU:22R) is 2026-07-14 Est..
Does ContraFect Corp(STU:22R) pay dividends? If so, how much?
ContraFect Corp(STU:22R) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Lucira Health, FuboTV, ContraFect, General Motors, or Luminar Technologies? | 2023-02-27 |
Articles on ContraFect Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers